Applied pharmacoeconomics. When can publication be legitimately withheld?

Area of Science:

• Health Economics
• Pharmaceutical Policy

Background:

• Pharmacoeconomic studies inform efficient drug treatment choices in cost-constrained healthcare systems.
• Perceptions of bias in economic evaluations limit the utility of pharmacoeconomic data for decision-makers.
• Methodological and ethical guidelines aim to improve the credibility of these studies.

Purpose of the Study:

• To evaluate issues concerning the publication of pharmacoeconomic study results.
• To advocate for pharmacoeconomics to be treated as a rigorous science, not marketing.
• To emphasize the importance of publishing all findings, regardless of sponsor favorability.

Main Methods:

• Article evaluates publication practices and ethical considerations in pharmacoeconomics.
• Compares pharmacoeconomic research publication standards to other scientific investigations.
• Discusses justifiable reasons for withholding publication of negative results.

Main Results:

• Pharmacoeconomic studies should undergo peer review and be published in reputable research journals.
• Publication of unfavorable results is encouraged to maintain scientific integrity.
• Withholding publication is acceptable for methodologically flawed studies or early-stage investigational drugs.

Conclusions:

• Transparency in publishing all pharmacoeconomic results is crucial for evidence-based healthcare.
• Increased access to all study outcomes, positive or negative, is essential for informed formulary decisions.
• Treating pharmacoeconomics as a science ensures its valuable contribution to healthcare policy.